Retatrutide has emerged as a new treatment in the fight against obesity. This novel drug, classified as a dual GLP-1 and GIP receptor agonist, shows promising results in clinical trials. By boosting these receptors, https://graysonjhnk145596.blogerus.com/58180866/tirzepatide-a-promising-new-treatment-for-obesity